MoonLake Immunotherapeutics
MLTX
MLTX
146 hedge funds and large institutions have $1.17B invested in MoonLake Immunotherapeutics in 2026 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 49 increasing their positions, 42 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
13% more funds holding
Funds holding: 129 → 146 (+17)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.5% less ownership
Funds ownership: 88.47% → 87.97% (-0.5%)
Holders
146
Holding in Top 10
3
Calls
$34M
Puts
$9.32M
Top Buyers
| 1 | +$30M | |
| 2 | +$29.8M | |
| 3 | +$22.8M | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$22.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$15.6M |
Top Sellers
| 1 | -$62.1M | |
| 2 | -$20.3M | |
| 3 | -$10M | |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.37M |
| 5 |
Morgan Stanley
New York
|
-$7.12M |
